Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion | Zendy

Thomas Kistler | Zendy; PM Ambhl | Zendy

Open Access

Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion

Author(s) -

Thomas Kistler,

PM Ambhl

Publication year - 2001

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2001.09680

Subject(s) - medicine , irbesartan , effective renal plasma flow , renal function , angiotensin ii , endocrinology , pharmacology , celecoxib , angiotensin ii receptor type 1 , cyclooxygenase , plasma renin activity , aldosterone , angiotensin receptor , renin–angiotensin system , renal blood flow , chemistry , blood pressure , biochemistry , enzyme

Drugs that either inhibit prostaglandin synthesis or antagonise angiotensin II effects are likely to impair renal function, especially in patients with an activated renin-angiotensin-aldosterone system. Of the former, nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used, and newer agents with cyclooxygenase 2 (COX-2) specific inhibition may have fewer renal side effects compared to non-selective NSAIDs. We therefore investigated whether combination of a COX-2 inhibitor with an angiotensin II subtype 1 (AT1) receptor blocker is safe with regard to preservation of normal renal function in a state of slight volume contraction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research